Protagonist Therapeutics Inc (PTGX) — Cash Flow-to-Debt Ratio
Protagonist Therapeutics Inc (PTGX) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of $-1.94 Million could theoretically repay 0% of its total liabilities ($56.25 Million) in one year. See Protagonist Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Protagonist Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Protagonist Therapeutics Inc across 11 annual periods. Also explore Protagonist Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Protagonist Therapeutics Inc (2014–2024)
Year-by-year debt coverage analysis for Protagonist Therapeutics Inc. For market capitalisation and broader financial context, see how much is Protagonist Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 2.65x | $184.15 Million | $69.43 Million | ▲ +180.3% |
| 2023 | -3.30x | $-70.24 Million | $21.27 Million | ▲ +1.3% |
| 2022 | -3.35x | $-108.14 Million | $32.32 Million | ▼ -47.9% |
| 2021 | -2.26x | $-107.86 Million | $47.67 Million | ▼ -40.0% |
| 2020 | -1.62x | $-72.48 Million | $44.86 Million | ▼ -191.6% |
| 2019 | -0.55x | $-41.53 Million | $74.95 Million | ▲ +70.1% |
| 2018 | -1.85x | $-49.95 Million | $26.96 Million | ▼ -2162.5% |
| 2017 | 0.09x | $3.87 Million | $43.10 Million | ▲ +101.9% |
| 2016 | -4.66x | $-29.97 Million | $6.43 Million | ▼ -70.0% |
| 2015 | -2.74x | $-14.38 Million | $5.25 Million | ▲ +16.0% |
| 2014 | -3.26x | $-7.74 Million | $2.37 Million | — |